Below, we examine the compound annual growth rate — CAGR for short — of an investment into Onconova Therapeutics shares, starting with a $10,000 purchase of ONTX, presented on a split-history-adjusted basis factoring in the complete ONTX split history. For prior years see complete reverse stock split history across our coverage universe. "Onconova Therapeutics' stock is owned by a variety of institutional and retail investors. See what's happening in the market right now with MarketBeat's real-time news feed.
More
Some companies that are related to Onconova Therapeutics include Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX.
P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Their forecasts range from $1.25 to $2.00. Onconova Therapeutics's stock reverse split before market open on Wednesday, September 26th 2018. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." The biopharmaceutical company had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.40 million. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.Get daily stock ideas top-performing Wall Street analysts. ONTX - Onconova Therapeutics, Inc.
The company has a license agreement with SymBio Pharmaceuticals Limited; a development and license agreement with Baxter Healthcare SA; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.Onconova Therapeutics' management team includes the following people:
The $5 and $10 pricepoints tend to be important in this regard. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split.4 brokers have issued 1-year price objectives for Onconova Therapeutics' shares. Company insiders that have bought Onconova Therapeutics stock in the last two years include Abraham N Oler, E Premkumar Reddy, James J Marino, Jerome Groopman, Mark Patrick Guerin, and Steven M Fruchtman.
This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. A reverse stock splits list, with links to full split history.
The reverse stock split will decrease the number of common shares issued and outstanding from approximately 85.11 million shares to approximately 5.67 million shares. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split.
The reverse split was approved by the Company’s shareholders on November 15, 2019 and will be effective as of the commencement of trading on January 7, 2020… Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
On average, they expect Onconova Therapeutics' stock price to reach $1.52 in the next year. Sign-up to receive the latest news and ratings for ONTX and its competitors with MarketBeat's FREE daily newsletter.Onconova Therapeutics' stock was trading at $0.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. View which stocks are hot on social media with MarketBeat's trending stocks report.Identify stocks that meet your criteria using seven unique stock screeners. The 1-15 reverse split was announced on Tuesday, September 25th 2018.